Journal of Surgical Research
Volume 146, Issue 1 , Pages 43-48 , 1 May 2008

ErbB3 mRNA Expression Correlated with Specific Clinicopathologic Features of Japanese Lung Cancers

Received 17 January 2007

References 

  1. Prenzel N, Fischer OM, Streit S, et al. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endcr Relat Cancer. 2001;8:11
  2. Guy PM, Platko JV, Cantray LC, et al. Insect cell-expressed p180erbB3 possesses an impaired tyrosine kinase activity. Proc Natl Acad Sci USA. 1994;91:8132
  3. Yarden Y, Sliwkowski MX. Untangling the ErbB signalling network. Nat Rev Mol Cell Biol. 2001;2:127
  4. Chan DC, Soriano A, Kane MA, et al. Biology of lung cancer. In:  Hansen HH editors. Textbook of lung cancer. London: Martin Dunitz; 2000;p. 53–54
  5. D’Amico TA, Massey M, Herndon JE, et al. A biologic risk model for stage I lung cancer: Immunohistochemical analysis of 408 patients with the use of ten molecular markers. J Thorac Cardiovasc Surg. 1999;117:736
  6. Yi ES, Harclerode D, Gondo M, et al. High c-erbB-3 protein expression is associated with shorter survival in advanced non-small cell lung carcinomas. Mod Pathol. 1997;10:142
  7. Lai WW, Chen FF, Wu MH, et al. Immunohistochemical analysis of epidermal growth factor receptor family members in stage I non-small cell lung cancer. Ann Thorac Surg. 2001;72:1868
  8. Amann J, Kalyankrishna S, Massion PP, et al. Aberrant epidermal growth factor signaling and enhanced sensitivity to EGFR inhibitors in lung cancer. Cancer Res. 2005;65:226
  9. Engleman JA, Janne PA, Mermel C, et al. ErbB3 mediates phosphoinositide 3-kinase activity in gefitinib sensitive non-small cell lung cell cancer cell lines. Proc Natl Acad Sci USA. 2005;102:3788
  10. Fujimoto N, Wislez M, Zhang J, et al. High expression of ErbB family members and their ligands in lung adenocarcinomas that are sensitive to inhibition of epidermal growth factor receptor. Cancer Res. 2005;65:11478
  11. Japan Lung Cancer Society. In: 5th ed.. General rule for clinical and pathological record of lung cancer. 5:Tokyo: The Japan Lung Cancer Society; 1999;p. 1–177
  12. Endo K, Konishi A, Sasaki H, et al. Epidermal growth factor receptor gene mutation in non-small cell lung cancer using highly sensitive and fast TaqMan PCR assay. Lung Cancer. 2006;50:375
  13. Riese DJ, Stern DF. Specificity within the EGF family/ErbB receptor family signaling network. BioEssays. 1998;20:41
  14. Olayioye MA, Neve RM, Lane HA, et al. The ErbB signaling network: Receptor heterodimerization in development and cancer. EMBO J. 2000;19:3159
  15. Sithanandam G, Fornwald LW, Fields J, et al. Inactivation of ErbB3 by siRNA promotes apoptosis and attenuates growth and invasiveness of human lung adenocarcinoma cell line A549. Oncogene. 2005;24:1847
  16. Poller DN, Spendlove I, Baker C, et al. Production and characterization of a polyclonal antibody to the c-erbB3 protein: Examination of c-erbB3 protein expression in adenocarcinoma. J Pathol. 1992;168:275
  17. Cappuzzo F, Toschi L, Domenichini I, et al. HER3 genomic gain and sensitivity to gefitinib in advanced non small-cell lung cancer patients. Br J Cancer. 2005;93:1334
  18. Ono M, Hirata A, Kometani T, et al. Sensitivity to gefitinib (Iressa, ZD1839) in non-small cell lung cancer cell lines correlates with dependence on the epidermal growth factor (EGF) receptor/extracellular signal-regulated kinase 1/2 and EGF receptor/Akt pathway for prolification. Mol Cancer Ther. 2004;3:465
  19. Engelman JA, Cantley LC. The role of the ErbB family members in non-small cell lung cancers sensitive to epidermal growth factor receptor kinase inhibitors. Clin Cancer Res. 2006;12:4372s
  20. Paez JG, Janne PA, Lee JC, et al. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science. 2004;304:1497
  21. Lynch TJ, Bell DW, Sordella R, et al. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004;350:2129
  22. Pao W, Miller V, Zakowski M, et al. EGF receptor gene mutations are common in lung cancers from “never smokers” and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA. 2004;101:13306
  23. Sasaki H, Shimizu S, Endo K, et al. EGFR and erbB2 mutation status in Japanese lung cancer patients. Int J Cancer. 2006;118:180
  24. Sasaki H, Endo K, Mizuno K, et al. EGFR mutation status and prognosis for gefitinib treatment in Japanese lung cancer. Lung Cancer. 2006;51:135
  25. Hua KT, Way TD, Lin JK. Pentagalloyglucose inhibits estrogen receptor alpha by lysosome-dependent depletion and modulates EebB/PI3K/Akt pathway in human breast cancer MCF-7 cells. Mol Carcinog. 2006;45:551
  26. St-Laurent V, Sanchez M, Charbonneau C, et al. Selective hormone-dependent repression of estrogen receptor beta by a p38-activated ErbB2/ErbB3 pathway. J Steroid Biochem Mol Biol. 2005;94:23

PII: S0022-4804(07)00385-X

doi: 10.1016/j.jss.2007.05.030

Journal of Surgical Research
Volume 146, Issue 1 , Pages 43-48 , 1 May 2008

Article Tools

* Image Usage & Resolution